Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Published in: Drugs & Therapy Perspectives 4/2024

28-04-2024 | Pustular Psoriasis | Drug Reactions and Interactions

Determine and remove the drug trigger, usually antibiotics, that causes acute generalised exanthematous pustulosis

Authors: Esther S. Kim, Connie Kang

Published in: Drugs & Therapy Perspectives | Issue 4/2024

Login to get access

Abstract

A wide range of drugs has been associated with the development of acute generalised exanthematous pustulosis (AGEP). Although AGEP is rare and typically self-limiting once the trigger is withdrawn, the reaction can be severe and even fatal in some cases. Prompt diagnosis and appropriate management can aid in minimizing adverse outcomes, and for this, an increased awareness of the triggers and presentation of AGEP would be helpful.
Literature
1.
Sidoroff A, Halevy S, Bavinck JN, et al. Acute generalized exanthematous pustulosis (AGEP)—a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113–9.CrossRefPubMed
2.
Creadore A, Desai S, Alloo A, et al. Clinical characteristics, disease course, and outcomes of patients with acute generalized exanthematous pustulosis in the US. JAMA Dermatol. 2022;158(2):176–83.CrossRefPubMed
3.
Moore MJ, Sathe NC, Ganipisetti VM. Acute generalized exanthematous pustulosis. StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2023.
4.
Al Aboud DM, Nessel TA, Hafsi W. Cutaneous adverse drug reaction. StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2024.
5.
Parisi R, Shah H, Navarini AA, et al. Acute generalized exanthematous pustulosis: clinical features, differential diagnosis, and management. Am J Clin Dermatol. 2023;24(4):557–75.CrossRefPubMed
6.
Vallejo-Yague E, Martinez-De la Torre A, Mohamad OS, et al. Drug triggers and clinic of acute generalized exanthematous pustulosis (AGEP): a literature case series of 297 patients. J Clin Med. 2022;11(2):397.CrossRefPubMedPubMedCentral
7.
Stadler P-C, Oschmann A, Kerl-French K, et al. Acute generalized exanthematous pustulosis: clinical characteristics, pathogenesis, and management. Dermatology. 2023;239(3):328–33.CrossRefPubMed
8.
Groot AC. Results of patch testing in acute generalized exanthematous pustulosis (AGEP): a literature review. Contact Dermatitis. 2022;87(2):119–41.CrossRefPubMed
9.
Barbaud A, Castagna J, Soria A. Skin tests in the work-up of cutaneous adverse drug reactions: a review and update. Contact Dermatitis. 2022;86(5):344–56.CrossRefPubMed
10.
Zheng J, Gao Y, Yi X, et al. A case of ceftriaxone-induced acute generalized exanthematous pustulosis/generalized pustular psoriasis overlap. Case Rep Dermatol. 2018;10(1):69–75.CrossRefPubMedPubMedCentral
11.
Oh DAQ, Yeo YW, Choo KJL, et al. Acute generalized exanthematous pustulosis: epidemiology, clinical course, and treatment outcomes of patients treated in an Asian academic medical center. JAAD Int. 2021;3:1–6.CrossRefPubMedPubMedCentral
12.
Yanes D, Nguyen E, Imadojemu S, et al. Cyclosporine for treatment of acute generalized exanthematous pustulosis: a retrospective analysis. J Am Acad Dermatol. 2020;83.
13.
Zhang L, Xu Q, Lin T, et al. Case report: successful treatment of acute generalized exanthematous pustulosis with secukinumab. Front Med (Lausanne). 2021;8: 758354.CrossRefPubMedPubMedCentral
14.
Meiss F, Helmbold P, Meykadeh N, et al. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases. J Eur Acad Dermatol Venereol. 2007;21(5):717–9.CrossRefPubMed
Metadata
Title
Determine and remove the drug trigger, usually antibiotics, that causes acute generalised exanthematous pustulosis
Authors
Esther S. Kim
Connie Kang
Publication date
28-04-2024
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives / Issue 4/2024
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.1007/s40267-024-01064-x

Other articles of this Issue 4/2024

Drugs & Therapy Perspectives 4/2024 Go to the issue

Adis Summary of Research

Adis Summary of Research: Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder

Drug Reactions and Interactions

Adjust antimicrobial agent regimens in older patients to correct for changes in pharmacokinetics and to avoid adverse events

Correction

Correction to: Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA

Original Research Article

Increasing patient safety due to an implemented ward pharmacist in an interprofessional cancer care team evaluated in a prospective, controlled intervention study

Original Research Article

Assessment of rational antibiotic use among children being treated in primary care facilities in Punjab, Pakistan: findings and implications